<SEC-DOCUMENT>0001213900-26-012759.txt : 20260205
<SEC-HEADER>0001213900-26-012759.hdr.sgml : 20260205
<ACCEPTANCE-DATETIME>20260205160520
ACCESSION NUMBER:		0001213900-26-012759
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20260205
DATE AS OF CHANGE:		20260205

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Polaryx Therapeutics, Inc.
		CENTRAL INDEX KEY:			0002075320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			WY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-95464
		FILM NUMBER:		26602866

	BUSINESS ADDRESS:	
		STREET 1:		140 EAST RIDGEWOOD AVENUE
		STREET 2:		SUITE 415, SOUTH TOWER
		CITY:			PARAMUS
		STATE:			NJ
		ZIP:			07652
		BUSINESS PHONE:		201-940-7236

	MAIL ADDRESS:	
		STREET 1:		SOUTH TOWER, 140 E RIDGEWOOD AVENUE
		STREET 2:		SUITE 415
		CITY:			PARAMUS
		STATE:			NJ
		ZIP:			07652

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Mstone Partners Healthcare Ltd
		CENTRAL INDEX KEY:			0002104809
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			K3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		7/F 80 GLOUCESTER ROAD
		CITY:			WANCHAI
		PROVINCE COUNTRY:   	K3
		ZIP:			00000
		BUSINESS PHONE:		852 2155 9599

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		7/F 80 GLOUCESTER ROAD
		CITY:			WANCHAI
		PROVINCE COUNTRY:   	K3
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Mstone Partners Healthcare Ltd -->
          <cik>0002104809</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common stock, par value $0.0001 per share ("Common Stock")</securitiesClassTitle>
      <dateOfEvent>01/29/2026</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0002075320</issuerCIK>
        <issuerCUSIP>73110F100</issuerCUSIP>
        <issuerName>Polaryx Therapeutics, Inc.</issuerName>
        <address>
          <com:street1>South Tower, 140 E Ridgewood Avenue</com:street1>
          <com:street2>Suite 415</com:street2>
          <com:city>Paramus</com:city>
          <com:stateOrCountry>NJ</com:stateOrCountry>
          <com:zipCode>07652</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Alex Keun Mo Yang</personName>
          <personPhoneNum>852-2155-0487</personPhoneNum>
          <personAddress>
            <com:street1>c/o Mstone Partners Healthcare Limited</com:street1>
            <com:street2>7/F, 80 Gloucester Road</com:street2>
            <com:city>Wan Chai</com:city>
            <com:stateOrCountry>K3</com:stateOrCountry>
            <com:zipCode>00000</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0002104809</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Mstone Partners Healthcare Limited</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>K3</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>22452954.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>22452954.00</sharedDispositivePower>
        <aggregateAmountOwned>22452954.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>47.4</percentOfClass>
        <typeOfReportingPerson>CO</typeOfReportingPerson>
        <commentContent>Based on 47,343,297 shares of common stock outstanding as of January 12, 2026.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonNoCIK>Y</reportingPersonNoCIK>
        <reportingPersonName>MBstone Biotech Flagship Limited</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>K3</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>183560.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>183560.00</sharedDispositivePower>
        <aggregateAmountOwned>183560.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>0.4</percentOfClass>
        <typeOfReportingPerson>CO</typeOfReportingPerson>
        <commentContent>Based on 47,343,297 shares of common stock outstanding as of January 12, 2026.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonNoCIK>Y</reportingPersonNoCIK>
        <reportingPersonName>Mstone Pediaorphan Singapore I Pte. Limited</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>U0</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>108282.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>108282.00</sharedDispositivePower>
        <aggregateAmountOwned>108282.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>0.2</percentOfClass>
        <typeOfReportingPerson>CO</typeOfReportingPerson>
        <commentContent>Based on 47,343,297 shares of common stock outstanding as of January 12, 2026.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0002103399</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Alex Keun Mo Yang</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>M5</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>22744796.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>22744796.00</sharedDispositivePower>
        <aggregateAmountOwned>22744796.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>48.0</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <commentContent>Based on 47,343,297 shares of common stock outstanding as of January 12, 2026.</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common stock, par value $0.0001 per share ("Common Stock")</securityTitle>
        <issuerName>Polaryx Therapeutics, Inc.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>South Tower, 140 E Ridgewood Avenue</com:street1>
          <com:street2>Suite 415</com:street2>
          <com:city>Paramus</com:city>
          <com:stateOrCountry>NJ</com:stateOrCountry>
          <com:zipCode>07652</com:zipCode>
        </issuerPrincipalAddress>
      </item1>
      <item2>
        <filingPersonName>This Schedule 13D is being filed jointly by (1) Mstone Partners Healthcare Limited, a private company limited by shares incorporated in Hong Kong ("Mstone"); (2) MBstone Biotech Flagship Limited, a private company limited by shares incorporated in Hong Kong ("MBstone"); (3) Mstone Pediaorphan Singapore I Pte. Limited, a private company limited by shares incorporated in Singapore ("Mstone Singapore"); and (4) Alex Keun Mo Yang (Mr. Yang, Mstone, MBStone and Mstone Singapore are collectively referred to herein as the "Reporting Persons"). The joint filing agreement of the Reporting Persons is attached as Exhibit 99.1 to this Schedule 13D.

Mr. Yang is the founder and Chief Executive Officer of Mstone, the Chief Executive Officer of MBstone and the Chief Executive Officer of Mstone Singapore. Mr. Yang has voting power over the securities held by Mstone, MBstone and Mstone Singapore. Mr. Yang disclaims beneficial ownership of the securities reported in this Schedule 13D other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13D shall not be deemed an admission that Mr. Yang is the beneficial owner of such securities for any other purpose.</filingPersonName>
        <principalBusinessAddress>The principal business address of each of Mstone, MBstone and Mr. Yang is 7/F, 80 Gloucester Road, Wan Chai, Hong Kong. The principal business address of Mstone Singapore is 33 Ubi Ave 3#08-61 Vertex Tower A, Singapore 408868.</principalBusinessAddress>
        <principalJob>The principal business of Mstone is serving as a biotechnology, healthcare, and AI incubator. The principal business of MBstone is investing in biotech and healthcare companies. The principal business of Mstone Singapore is serving as a holding company for biopharmaceutical drug development. The principal occupation of Mr. Yang is to serve as the founder and Chief Executive Officer of Mstone, the Chief Executive Officer of MBstone and the Chief Executive Officer of Mstone Singapore, as well as Chief Executive Officer of Polaryx Therapeutics, Inc. (the "Company").</principalJob>
        <hasBeenConvicted>During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).</hasBeenConvicted>
        <convictionDescription>During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceedings was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect at such laws.</convictionDescription>
        <citizenship>Mstone is a private company limited by shares incorporated in Hong Kong. MBstone is a private company limited by shares incorporated in Hong Kong. Mstone Singapore is a private company limited by shares incorporated in Singapore. Mr. Yang is a citizen of South Korea.</citizenship>
      </item2>
      <item3>
        <fundsSource>In aggregate, the Reporting Persons have voting and dispositive power over 22,744,796 shares of Common Stock. The aggregate purchase price of the shares of Common Stock purchased and currently owned by the Reporting Persons is $3,000,513. The source of the funding for the purchases of the shares of Common Stock was the general working capital of the Reporting Persons. The information set forth in Item 4 below is incorporated herein by reference.</fundsSource>
      </item3>
      <item4>
        <transactionPurpose>The Reporting Persons own 48.0% of the Company in the aggregate, based on 47,343,297 shares of Common Stock outstanding as of January 12, 2026.

Mr. Yang serves as Chief Executive Officer and as a member of the board of directors of the Company (the "Board"), and, in such capacity, may have influence over the corporate activities of the Company, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

Except as described in this Schedule 13D, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, although, the Reporting Persons, at any time and from time to time, may review, reconsider and change their position and/or change their purpose and/or develop such plans and may seek to influence management or the Board with respect to the business and affairs of the Company and may from time to time consider pursuing or proposing such matters with advisors, the Company or other persons.</transactionPurpose>
      </item4>
      <item5>
        <percentageOfClassSecurities>The information set forth in Items 2 and 3 and on the cover pages of this Schedule 13D is incorporated by reference in its entirety into this Item 5. The percentages used in this Schedule 13D are calculated based on 47,343,297 shares of Common Stock outstanding as of January 12, 2026.</percentageOfClassSecurities>
        <numberOfShares>See Item 5(a) hereof.</numberOfShares>
        <transactionDesc>N/A.</transactionDesc>
        <listOfShareholders>Except as otherwise described in this Item 5, no one other than the Reporting Persons has the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, any of the Common Stock beneficially owned by the Reporting Persons as described in this Item 5.</listOfShareholders>
        <date5PercentOwnership>N/A.</date5PercentOwnership>
      </item5>
      <item6>
        <contractDescription>None.</contractDescription>
      </item6>
      <item7>
        <filedExhibits>Exhibit 99.1     Joint Filing Agreement</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Mstone Partners Healthcare Limited</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Alex Keun Mo Yang</signature>
          <title>Chief Executive Officer</title>
          <date>02/05/2026</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>MBstone Biotech Flagship Limited</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Alex Keun Mo Yang</signature>
          <title>Chief Executive Officer</title>
          <date>02/05/2026</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Mstone Pediaorphan Singapore I Pte. Limited</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Alex Keun Mo Yang</signature>
          <title>Chief Executive Officer</title>
          <date>02/05/2026</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Alex Keun Mo Yang</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Alex Keun Mo Yang</signature>
          <title>Reporting person</title>
          <date>02/05/2026</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea027550001ex99-1_polaryx.htm
<DESCRIPTION>JOINT FILING AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AGREEMENT REGARDING JOINT FILING</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OF STATEMENT ON SCHEDULE 13D OR 13G</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">In accordance with Rule 13d-1(k) under the Securities Exchange Act
of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any
and all amendments thereto) with respect to the Common stock, par value $0.0001 per share, of Polaryx Therapeutics, Inc. and further agree
that this Joint Filing Agreement shall be included as an exhibit to such joint filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">The undersigned further agree that each party hereto is responsible
for the timely filing of such Statement on Schedule 13D and any amendments thereto, and for the accuracy and completeness of the information
concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information
concerning any other party, unless such party knows or has reason to believe that such information is inaccurate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This Joint Filing Agreement may be signed in counterparts
with the same effect as if the signature on each counterpart were upon the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: February 5, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MSTONE PARTNERS HEALTHCARE LIMITED</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MBSTONE BIOTECH FLAGSHIP LIMITED</B></FONT></TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&nbsp;<I>Alex Keun Mo Yang</I></FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ <I>Alex
    Keun Mo Yang</I></FONT></TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alex Keun Mo Yang</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alex Keun Mo Yang</FONT></TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MSTONE PEDIAORPHAN SINGAPORE I PTE. LIMITED</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&nbsp;<I>Alex Keun Mo Yang</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ <I>Alex
    Keun Mo Yang</I></FONT></TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alex Keun Mo Yang</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alex Keun Mo Yang</FONT></TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
